Loading patent…
AssigneesBiomerieux, Universite des Sciences et Technologies de Lille
InventorsEric Adriaenssens, Genevieve Choquet-Kastylevsky, Laurent Dolle, Ikram El-Yazidi Belkoura, Hubert Hondermarck
Estimating the term…
The present invention concerns a method for the in vitro diagnosis of breast cancer which consists in determining the presence of NGF in a biological sample derived from a patient suspected of suffering from breast cancer. Said method may be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in the diagnosis of relapse in the case of breast cancer. The present invention also concerns the use of an NGF binding partner or of an NGF inhibitor for preparing a medicinal product, said medicinal product being in particular useful for blocking tumor proliferation and remote dissemination in patients suffering from breast cancer.
A method for the in vitro diagnosis of breast cancer, characterized in that it consists in determining the presence of NGF in a biological sample derived from a patient suspected of suffering from breast cancer.
The use of an NGF binding partner or of an NGF inhibitor for preparing a medicinal product, it being understood that, in the case of cancer, the NGF binding partners are not receptors for NGF or active fragments of these receptors.
A pharmaceutical composition, characterized in that in that comprises, as active principle, at least one NGF binding partner or one NGF inhibitor, optionally combined with a pharmaceutically acceptable excipient, it being understood that, in the case of cancer, the NGF binding partners are not receptors for NGF or active fragments of these receptors.
A method of treating breast cancer which comprises the administration, to a patient, of an effective dose of an NGF binding partner or of an NGF inhibitor.
Dependencies are inferred from the claim text.